Pharmaceutics (Nov 2022)

Bioorthogonal Chemistry Approach for the Theranostics of GRPR-Expressing Cancers

  • Alice D’Onofrio,
  • Francisco Silva,
  • Lurdes Gano,
  • Paula Raposinho,
  • Célia Fernandes,
  • Arkadiusz Sikora,
  • Monika Wyczółkowska,
  • Renata Mikołajczak,
  • Piotr Garnuszek,
  • António Paulo

DOI
https://doi.org/10.3390/pharmaceutics14122569
Journal volume & issue
Vol. 14, no. 12
p. 2569

Abstract

Read online

Several gastrin-releasing peptide receptor (GRPR) antagonists with improved in vivo behavior have been recently developed and tested in the clinic. However, despite the generally mild side effects of peptide receptor radionuclide therapy (PRRT), toxicity has been observed due to high doses delivered to nontarget tissues, especially in the kidneys and pancreas. Previous experiences with radiolabeled peptides opened a unique opportunity to explore GRPR pretargeting using clickable bombesin antagonists. Toward this goal, we used clickable DOTA-like radiocomplexes which have been previously evaluated by our group. We functionalized a potent GRPR antagonist with a clickable TCO moiety using two different linkers. These precursors were then studied to select the compound with the highest GRPR binding affinity and the best pharmacokinetics to finally explore the advantages of the devised pretargeting approach. Our results provided an important proof of concept toward the development of bioorthogonal approaches to GRPR-expressing cancers, which are worth investigating further to improve the in vivo results. Moreover, the use of clickable GRPR antagonists and DOTA/DOTAGA derivatives allows for fine-tuning of their pharmacokinetics and metabolic stability, leading to a versatile synthesis of new libraries of (radio)conjugates useful for the development of theranostic tools toward GRPR-expressing tumors.

Keywords